Navigation Links
Drug-Eluting Stents Outperform Bare Stents in Heart Attack
Date:3/30/2008

ively, at 30 days and 12.3 percent vs. 9.9 percent, respectively, at eight months. The rates of minor and major bleeding did not differ in the two groups, but a marked drop in the blood platelet count -- a complication that could cause uncontrolled bleeding -- was more common among patients treated with abciximab (4.0 percent vs. 0.8 percent, p=0.004).

When comparing the two types of stents, investigators found an equivalent MACE rate at 30 days (3.9 percent vs. 5.9 percent, p=0.12) with sirolimus-eluting and bare-metal stents. However, at eight months, the MACE rate was significantly lower with drug-eluting stents (7.8 percent vs. 14.5 percent, p=0.0039). This difference was mainly driven by a 69 percent reduction in the need for a repeat procedure to reopen the treated coronary artery (3.2 percent with sirolimus-eluting stents vs. 10.2 percent with bare-metal stents, p=0.0004). The rates of death and repeat heart attack were similar, as was the incidence of stent thrombosis.

"Our study shows that tirofiban is 'noninferior' in its efficacy to abciximab in this high-risk patient population, and has a better safety profile," said Dr. Valgimigli. "We have also confirmed that, even in STEMI patients, drug-eluting stents are highly effective in reducing reintervention in the target vessel. More important, this came without an extra price to pay in terms of death, myocardial infarction or stent thrombosis."

Dr. Valgimigli will present the results of this study on Sunday, March 30 at 9:00 a.m. CDT in the Grand Ballroom, S100. This study will simultaneously publish in JAMA: Journal of the American Medical Association.

About SCAI

Headquartered in Washington, DC, the Society for Cardiovascular Angiography and Interventions is a 4,000-member professional organization representing invasive and interventional cardiologists in over 60 nations. SCAI's mission is to promote excellence in invasive and interventional cardiovascular medicine through
'/>"/>

SOURCE SCAI-ACCi2
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
2. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
3. OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) has Lower MACE Rate than TAXUS(R) and CYPHER(R) Stents in Clinical Trial
4. Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
5. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
6. Medifast Outperforms American Diabetes Association Diet by Twice the Weight Loss According to Published Study
7. BRAVE-3 Questions Value of Abciximab in PCI for Heart Attack
8. Stem Cell Research Provides Medical Breakthrough to Repair Heart Cell Damage Created by a Heart Attack
9. DuraHeart(TM) LVAS Receives Conditional Approval for US Pivotal Trial
10. American Heart Association Journal Report: Reducing Kids Salt Intake May Lower Soft Drink Consumption, Reducing Obesity, High Blood Pressure and Later Health Risks
11. Boston Scientific Announces CE Mark Approval for New Devices to Treat Heart Failure and Sudden Cardiac Death
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... N.J. , March 27, 2015  Johnson & Johnson ... Shareholders at 10 a.m. (Eastern Time) on Thursday, April 23, ... N.J. Investors and other interested parties ... visiting the Company,s website at www.jnj.com and clicking ... from the meeting will be made available a few hours ...
(Date:3/27/2015)... , March 27, 2015  WebMD Health ... source of health information, today announced an ... National Action Plan for Combating Antibiotic-Resistant ... emphasized the urgency and importance of addressing ... and global health.    The WebMD ...
(Date:3/26/2015)... WASHINGTON , March 26, 2015 "Whether ... potentially patients one day." In a single ... and chief scientific officer at Pfizer,s Centers for ... researchers and scientists fueling progress at America,s biopharmaceutical companies. ... to work side-by-side with academia, patient foundations and the ...
Breaking Medicine Technology:Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 2Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 3Collaboration for Cures: Teaming Up to Advance Science and Save Lives 2
... Results from two prospective, double-blind placebo controlled multi-center ... pooled European efficacy and safety data in patients with ... presented at the American Academy of Neurology,s (AAN) 61st ... by Merz Pharmaceuticals, which plans to file a Biologic ...
... AS, the human antibody,therapeutics company, announced today that ... were presented by its,collaboration partner Peregrine Pharmaceuticals at ... Cancer Research (AACR) 2009 held during April,18 - ... of PGN635 and PGN632,provided further confirmatory evidence that ...
Cached Medicine Technology:Merz Pharmaceuticals Announces Results of Three Clinical Trials With NT-201 (Botulinum Neurotoxin Type A Free From Complexing Proteins) in Movement Disorder Patients 2Merz Pharmaceuticals Announces Results of Three Clinical Trials With NT-201 (Botulinum Neurotoxin Type A Free From Complexing Proteins) in Movement Disorder Patients 3Merz Pharmaceuticals Announces Results of Three Clinical Trials With NT-201 (Botulinum Neurotoxin Type A Free From Complexing Proteins) in Movement Disorder Patients 4Merz Pharmaceuticals Announces Results of Three Clinical Trials With NT-201 (Botulinum Neurotoxin Type A Free From Complexing Proteins) in Movement Disorder Patients 5Affitech-Discovered Anti-PS Antibodies in Development by Peregrine Pharmaceuticals Show Excellent Functionality in Preclinical Studies 2
(Date:3/28/2015)... March 28, 2015 Take a bite ... kicks into action. Acids tumble into the stomach, ready ... faulty valve-like structure lets these acids run amok, triggering ... extremely common symptom. More than 60 million Americans have ... examine where heartburn starts, and how it can be ...
(Date:3/28/2015)... 28, 2015 Emergency Medical Care (EMC), ... in Manhattan, recently commemorated its three-year anniversary of being ... In addition to 24-hour urgent care, Emergency Medical Care ... At this time, Emergency Medical Care’s Urgent Care ... chest pain, eye injuries, ear infections, fevers, insect bites, ...
(Date:3/28/2015)... March 28, 2015 Pitching speed, player’s height, ... of shoulder and elbow injuries, according to new research released ... AOSSM ) Specialty Day. , “Our findings indicate that a ... increase in likelihood of a history of injury, a 10 ... 12% increase likelihood of a history of injury, and playing ...
(Date:3/28/2015)... NV (PRWEB) March 28, 2015 Early ... patients with Type V AC joint injuries, according to ... presented today at the American Orthopaedic Society for Sports ... returned to duty faster when surgery was not performed. ... with 7 receiving surgical treatment and 17 receiving non-surgical ...
(Date:3/28/2015)... Aureus Medical Group (web: aureusmedical.com), ... therapy jobs, has announced that it will participate ... Association Annual Conference to be held April 10-11, ... Columbus, OH. , The OPTA Annual Conference ... products and services. , Representatives from Aureus ...
Breaking Medicine News(10 mins):Health News:Bypass Your Heartburn Worries This Easter With Tylers Coffee 2Health News:Emergency Medical Care Celebrates Three Years of 24/7 Walk-In Urgent Care Services 2Health News:Researchers Highlight Shoulder and Elbow Injury Possibility in Youth Players 2Health News:For Type V AC Joint Injuries, Early Surgery May Not Be the Best Approach 2Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the Ohio Physical Therapy Association Annual Conference 2
... HealthDay Reporter , MONDAY, Nov. 8 (HealthDay News) -- ... must make in order to breast-feed is their sleep. But ... The study, published online Nov. 8 in the journal ... amount of time whether they were breast-feeding or formula-feeding. ...
... The use of statins among a group of postmenopausal ... to the results of a prospective analysis of data from ... results of our study are consistent with the majority of ... among users of statins," said Michael S. Simon, M.D., professor ...
... found that chemicals used to line junk food wrappers ... being ingested by people where they are contributing to ... acids or PFCAs are the breakdown products of chemicals ... ranging from kitchen pans to clothing to food packaging. ...
... (HealthDay News) -- Among certain patients with a history ... Pradaxa (dabigatran) appears to be as effective as the ... German research reveals. Specifically, the new study suggests ... stroke as effectively as warfarin among those facing an ...
... Breast cancer patients are more likely to have joint pain ... cancer, according to a study presented at the American College ... study is one of the first to identify factors that ... from AI therapy. AIs, the standard adjuvant therapy for ...
... an amphibious fish stays alive for up to two months on ... fishonly about an inch or two longthat live in temporary pools ... Florida. During dry seasons when their pools disappear, the fish hole ... stay moist, they can survive for extended periods out of water ...
Cached Medicine News:Health News: Breast-Feeding Won't Rob Mom of Sleep: Study 2Health News: Breast-Feeding Won't Rob Mom of Sleep: Study 3Health News:Statins did not reduce colorectal cancer in WHI analysis 2Health News:Dangerous chemicals in food wrappers likely migrating to humans: U of T study 2Health News:New Drug, Pradaxa, May Prevent Second Stroke in Certain Heart Patients 2Health News:New Drug, Pradaxa, May Prevent Second Stroke in Certain Heart Patients 3Health News:Study sheds light on aromatase inhibitor joint pain syndrome 2Health News:Study sheds light on aromatase inhibitor joint pain syndrome 3Health News:Special skin keeps fish species alive on land 2
Angled 45 degree shafts with 10.5 mm tying and 1 mm of tip crisscross serrated. Serrated handle with dull finish. Manufactured in titanium. Overall length 3.2 inches....
Straight, 7 mm tying platform. Castroviejo handle. Manufactured in titanium. Overall length 4.2 inches....
Straight shafts with 6 mm tying platform. Wide serrated handle with polished finish. Overall length 4.3 inches. Overall length 4.3 inches....
Curved shafts and tips with 6.5 mm tying platform. Flat serrated handle with dull finish. Overall length 3.9 inches. Overall length 3.9 inches....
Medicine Products: